Oncolytic virus’ past in question but promising future lyse ahead March 16, 2021 By Randy Osborne No Comments When Amgen Inc. won approval of the oncolytic virus (OV) therapy Imlygic (talimogene laherparepvec, t-vec) for melanoma in late October 2015, hopes ran high for the space. The mood has since faded in some quarters – but hardly all.Read More